Painreform Ltd (PRFX)

2026-04-28T13:13:35.000Z - 15 days ago

PRF Technologies announces FDA clearance of OcuRing-K NDA

Apr 28, 2026, 8:00 AM EDT - 15 days ago

PRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical Trial

Mar 27, 2026, 8:00 AM EDT - 6 weeks ago

PRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms

2026-03-17T12:55:36.000Z - 2 months ago

PRF Technologies signs commercial collaboration agreement with Blade Ranger

Mar 17, 2026, 8:30 AM EDT - 2 months ago

PRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial Engagements

2026-02-18T14:25:31.000Z - 2 months ago

PRF Technologies’ DeepSolar announces commercial due diligence engagement

Feb 18, 2026, 9:15 AM EST - 2 months ago

PRF Technologies' DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable Energy

2026-02-11T13:41:18.000Z - 3 months ago

PRF Technologies signs SaaS agreement with Shikun & Binui Energy

Feb 11, 2026, 8:30 AM EST - 3 months ago

PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial Base

2026-02-06T00:50:31.000Z - 3 months ago

PRF Technologies Ltd trading halted, news pending

2026-01-20T14:20:31.000Z - 4 months ago

PRF files first patent application for solar plant-level micro-climate modeling

Jan 20, 2026, 9:05 AM EST - 4 months ago

PRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy

2026-01-15T21:10:29.000Z - 4 months ago

PainReform changes name to PRF Technologies

Jan 15, 2026, 4:05 PM EST - 4 months ago

PainReform Ltd. Changes Name to PRF Technologies Ltd.

2026-01-12T14:22:52.000Z - 4 months ago

PainReform announces safety data supporting development of OcuRing-K platform

Jan 12, 2026, 9:00 AM EST - 4 months ago

PainReform's LayerBio's Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies

2026-01-05T14:15:52.000Z - 4 months ago

PainReform’s DeepSolar launches Smart TDD service

Jan 5, 2026, 9:00 AM EST - 4 months ago

PainReform's DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A Market

Dec 30, 2025, 8:48 AM EST - 4 months ago

BladeRanger to Showcase Advanced Green Energy Technologies at Abu Dhabi Sustainability Week

2025-12-10T13:50:56.000Z - 5 months ago

PainReform completed R&D assessment of LayerBio’s drug-delivery platform

Dec 10, 2025, 8:30 AM EST - 5 months ago

PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to Accommodate Multiple Drug Entities

2025-12-02T14:25:25.000Z - 5 months ago

PainReform commences development plan for OcuRing-K Phase II trial

Dec 2, 2025, 9:15 AM EST - 5 months ago

PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular Therapy

2025-11-12T14:10:39.000Z - 6 months ago

PainReform’s DeepSolar advances development of AI-driven reporting engine

Nov 12, 2025, 9:00 AM EST - 6 months ago

PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis

Nov 5, 2025, 8:30 AM EST - 6 months ago

PainReform's DeepSolar, Developing “DeepSolar Predict” within the NVIDIA Connect Program, Featured in The Market Link's “Watchlist Interview” and Announces Progress Toward Pilot Projects

2025-10-01T13:35:32.000Z - 7 months ago

PainReform reports 1H EPS ($1.09) vs. ($63.15) last year

Oct 1, 2025, 9:27 AM EDT - 8 months ago

PainReform Provides Business Update for the Six Months Ended June 30, 2025

2025-08-19T12:50:33.000Z - 9 months ago

PainReform’s DeepSolar accepted into Nvidia Connect Program

NVDA

Aug 19, 2025, 8:30 AM EDT - 9 months ago

PainReform/DeepSolar Accepted into NVIDIA Connect Program

2025-08-13T12:40:28.000Z - 9 months ago

PainReform completes strategic investment in LayerBio

Aug 13, 2025, 8:30 AM EDT - 9 months ago

PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System

2025-07-10T12:35:09.000Z - 10 months ago

PainReform expands pain management pipeline into opthamology with Layerbio deal

Jul 10, 2025, 8:30 AM EDT - 10 months ago

PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio

May 27, 2025, 12:12 PM EDT - 1 year ago

Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales

May 7, 2025, 4:30 PM EDT - 1 year ago

PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar Projects

2025-05-02T20:35:12.000Z - 1 year ago

PainReform files to sell 3.26M ordinary shares for holders

2025-04-10T12:41:14.000Z - 1 year ago

PainReform announces expansion into SEM sector

Apr 10, 2025, 8:30 AM EDT - 1 year ago

PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market

2025-04-07T21:05:27.000Z - 1 year ago

PainReform says shareholder equity now exceeds required threshold

Apr 7, 2025, 5:00 PM EDT - 1 year ago

PainReform Provides Year-End Business Update

2025-03-05T16:06:15.000Z - 1 year ago

PainReform completes acquisition of DeepSolar

Mar 5, 2025, 11:00 AM EST - 1 year ago

PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics

Feb 18, 2025, 8:30 AM EST - 1 year ago

PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

Dec 27, 2024, 8:30 AM EST - 1 year ago

PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110

Nov 20, 2024, 8:30 AM EST - 1 year ago

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

Nov 7, 2024, 5:00 PM EST - 1 year ago

PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Sep 11, 2024, 8:30 AM EDT - 1 year ago

PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110

Sep 10, 2024, 9:46 AM EDT - 1 year ago

PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds

Aug 20, 2024, 8:30 AM EDT - 1 year ago

PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

Aug 7, 2024, 10:00 AM EDT - 1 year ago

PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses

Aug 1, 2024, 8:30 AM EDT - 1 year ago

PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature

May 31, 2024, 4:15 PM EDT - 2 years ago

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

May 15, 2024, 4:05 PM EDT - 2 years ago

PainReform Provides Business Update for the First Quarter of 2024

May 8, 2024, 8:30 AM EDT - 2 years ago

PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com

Apr 18, 2024, 2:19 PM EDT - 2 years ago

PainReform Announces Closing of $4 Million Public Offering

Apr 9, 2024, 9:00 AM EDT - 2 years ago

PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

Apr 2, 2024, 8:30 AM EDT - 2 years ago

PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

Jan 22, 2024, 8:30 AM EST - 2 years ago

PainReform to Present at the Microcap Conference in Atlantic City

Jan 3, 2024, 8:30 AM EST - 2 years ago

PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief

Dec 26, 2023, 6:00 PM EST - 2 years ago

PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds

Nov 15, 2023, 4:05 PM EST - 2 years ago

PainReform Provides Business Update for the Third Quarter of 2023

Sep 11, 2023, 8:30 AM EDT - 2 years ago

PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File

Sep 7, 2023, 10:00 AM EDT - 2 years ago

PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary

Sep 5, 2023, 8:30 AM EDT - 2 years ago

PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City

Aug 10, 2023, 4:05 PM EDT - 2 years ago

PainReform Provides Business Update for the Second Quarter of 2023

Jul 19, 2023, 9:00 AM EDT - 3 years ago

PainReform Regains Compliance with Nasdaq Continued Listing Requirements

Jul 14, 2023, 2:35 PM EDT - 3 years ago

PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement

Jul 12, 2023, 9:05 AM EDT - 3 years ago

PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement

Jun 15, 2023, 8:30 AM EDT - 3 years ago

PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st